UNLABELLED: Despite the high frequency of HCV and HIV coinfection, little is known about HCV quasispecies in HIV-positive patients. The current analysis included 236 HIV+/anti-HCV+ women enrolled in the Women's Interagency HIV Study (WIHS). Hypervariable region 1 of the second envelope gene was analyzed by single-strand conformation polymorphism (SSCP). The relationship between the HCV quasispecies and clinical and demographic features were analyzed in multivariate models. Age over 40 years and high HCV RNA load were the only factors significantly associated with quasispecies complexity, assessed as the number of SSCP bands. High HIV and HCV plasma loads were associated with quasispecies stability over time, as reflected by stable SSCP band patterns. However, women who were actively injecting drugs were 3 times more likely to experience quasispecies changes than their noninjecting counterparts. No affect on HCV quasispecies dynamics was noted in relation to CD4 count or highly active antiretroviral therapy (HAART). CONCLUSION: among HIV/HCV coinfected patients, HCV quasispecies complexity and dynamics correlate more closely with HIV and HCV plasma loads than with CD4+ cell counts. Active drug use is associated with quasispecies changes probably due to repeated superinfections with new HCV strains. This needs to be considered when planning treatment and prevention strategies for HCV in coinfected individuals.
UNLABELLED: Despite the high frequency of HCV and HIV coinfection, little is known about HCV quasispecies in HIV-positivepatients. The current analysis included 236 HIV+/anti-HCV+ women enrolled in the Women's Interagency HIV Study (WIHS). Hypervariable region 1 of the second envelope gene was analyzed by single-strand conformation polymorphism (SSCP). The relationship between the HCV quasispecies and clinical and demographic features were analyzed in multivariate models. Age over 40 years and high HCV RNA load were the only factors significantly associated with quasispecies complexity, assessed as the number of SSCP bands. High HIV and HCV plasma loads were associated with quasispecies stability over time, as reflected by stable SSCP band patterns. However, women who were actively injecting drugs were 3 times more likely to experience quasispecies changes than their noninjecting counterparts. No affect on HCV quasispecies dynamics was noted in relation to CD4 count or highly active antiretroviral therapy (HAART). CONCLUSION: among HIV/HCV coinfectedpatients, HCV quasispecies complexity and dynamics correlate more closely with HIV and HCV plasma loads than with CD4+ cell counts. Active drug use is associated with quasispecies changes probably due to repeated superinfections with new HCV strains. This needs to be considered when planning treatment and prevention strategies for HCV in coinfected individuals.
Authors: M Carneiro; X F Yu; C Lyles; A Templeton; A E Weisstein; M Safaeian; H Farzadegan; D Vlahov; R B Markham Journal: J Infect Dis Date: 1999-10 Impact factor: 5.226
Authors: Y Benhamou; M Bochet; V Di Martino; F Charlotte; F Azria; A Coutellier; M Vidaud; F Bricaire; P Opolon; C Katlama; T Poynard Journal: Hepatology Date: 1999-10 Impact factor: 17.425
Authors: Shruti H Mehta; Andrea Cox; Donald R Hoover; Xiao-Hong Wang; Qing Mao; Stuart Ray; Steffanie A Strathdee; David Vlahov; David L Thomas Journal: Lancet Date: 2002-04-27 Impact factor: 79.321
Authors: Margaret C Shuhart; Daniel G Sullivan; Kirubeal Bekele; Robert D Harrington; Mari M Kitahata; Terri L Mathisen; Lisa V Thomassen; Scott S Emerson; David R Gretch Journal: J Infect Dis Date: 2006-03-28 Impact factor: 5.226
Authors: Hongxing Qin; Norah J Shire; Erica D Keenan; Susan D Rouster; M Elaine Eyster; James J Goedert; Margaret James Koziel; Kenneth E Sherman Journal: Blood Date: 2004-09-16 Impact factor: 22.113
Authors: Raymond T Chung; Scott R Evans; Yijun Yang; Dickens Theodore; Hernan Valdez; Rebecca Clark; Cecilia Shikuma; Thomas Nevin; Kenneth E Sherman Journal: AIDS Date: 2002-09-27 Impact factor: 4.177
Authors: Mark H Kuniholm; Andrea Kovacs; Xiaojiang Gao; Xiaonan Xue; Darlene Marti; Chloe L Thio; Marion G Peters; Norah A Terrault; Ruth M Greenblatt; James J Goedert; Mardge H Cohen; Howard Minkoff; Stephen J Gange; Kathryn Anastos; Melissa Fazzari; Tiffany G Harris; Mary A Young; Howard D Strickler; Mary Carrington Journal: Hepatology Date: 2010-05 Impact factor: 17.425
Authors: Mark H Kuniholm; Xiaojiang Gao; Xiaonan Xue; Andrea Kovacs; Darlene Marti; Chloe L Thio; Marion G Peters; Ruth M Greenblatt; James J Goedert; Mardge H Cohen; Howard Minkoff; Stephen J Gange; Kathryn Anastos; Melissa Fazzari; Mary A Young; Howard D Strickler; Mary Carrington Journal: J Infect Dis Date: 2011-06-15 Impact factor: 5.226
Authors: Paul Shapshak; Charurut Somboonwit; Lydia N Drumright; Simon D W Frost; Deborah Commins; Timothy L Tellinghuisen; William K Scott; Robert Duncan; Clyde McCoy; J Bryan Page; Brian Giunta; Francisco Fernandez; Elyse Singer; Andrew Levine; Alireza Minagar; Oluwadayo Oluwadara; Taiwo Kotila; Francesco Chiappelli; John T Sinnott Journal: Mol Diagn Ther Date: 2009 Impact factor: 4.074
Authors: Kenneth E Sherman; Susan D Rouster; Sandra Stanford; Jason T Blackard; Norah Shire; Margaret Koziel; Marion Peters; Raymond T Chung Journal: J Infect Dis Date: 2010-03 Impact factor: 5.226
Authors: Jennifer Price; Yifei Ma; Adaora Adimora; Margaret Fischl; Audrey L French; Elizabeth T Golub; Deborah Konkle-Parker; Mark H Kuniholm; Ighovwerha Ofotokun; Michael Plankey; Anjali Sharma; Phyllis C Tien Journal: BMJ Open Date: 2022-04-07 Impact factor: 2.692